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Given the ever-increasing advances of digital microfluidic biochips and their 
application in a wide range of areas including bio-chemistry experiments, 
diagnostics, and monitoring purposes like air and water quality control and etc., 
development of automated design flow algorithms for digital microfluidic biochips 
is of great importance. During the course of last decade there have been numerous 
researches on design, adaptation and optimization of algorithms for automation of 
digital microfluidic biochips synthesis flow. 
However, the initial assumption of researchers about absence of faults and 
deficiencies before and during execution of bio-assays has been proven always not 
to be the case. Thus, during the past few years researchers have placed great focus 
on fault-tolerance and fault-recovery of digital microfluidic biochips. 
In this dissertation we initially introduce proposed architectures for pin-
constrained digital microfluidic biochips; the proposed architectures are designed 
with the aim of improving overall functionality and also at the same time 
ameliorating fault-tolerance of digital microfluidic biochips in mind. 
The proposed architectures in this dissertation include general-purpose field-
programmable pin-constrained architecture and field-programmable cell array pin-
constrained architecture. Comparing the general-purpose field-programmable pin-
constrained architecture versus the base architecture dimension of the array of 
electrodes is reduced by 33%. Also, regarding number of electrodes and controlling 
pins 20% and 3% reductions are observed, respectively. Both architectures provide 
similar performance in terms of microfluidic operation times. However, droplet 
routing times are reduced by 17%. Finally, given the aforementioned factors 2% 
reduction is achieved in total times. 
Considering the base architecture versus the field-programmable cell array 
architecture dimension of array of electrodes is reduced by 10%. Regarding the 
number of electrodes and controlling pins 1% and 8% reductions are observed, 
respectively. Both architectures provide similar performance in terms of 
microfluidic operation times. Regarding droplet routing time 12% reduction, 
versus the base architecture, is achieved. Finally, considering the total bioassay 
execution time 1% reduction is achieved. 
Next, we explain fault-tolerance concepts within the context of pin-constrained 
digital microfluidic biochips; then we attempt to investigate fault-tolerance of the 
proposed digital microfluidic architectures versus the base architecture in presence 
of faults occurrences affecting mixing modules and Split / Storage / Detection 
(SSD) modules.
 1 
C h a p t e r  1  
MICROFLUIDICS 
Over the past decade, microfluidics as a valuable technology has played an 
important role in automating and minimizing biochemical processes. Microfluidic 
devices allow us to use much less fluid (on a volumetric scale) than conventional 
fluids in milliliters, as well as conventional laboratory devices, and there is no need 
for conventional laboratory devices. Residual technology enables us to perform 
many chemical experiments on laboratory devices on a chip (i.e. Lab-On-Chip 
(LoC). Laboratory devices on a chip perform a variety of biochemical functions 
such as diagnostic tests (In-Vitro) and immunoassays, DNA polymerase chain 
reaction (PCR) [1]. 
This thesis addresses digital microfluidic biochips (DMFB), in which the droplets 
are controlled individually and simultaneously on a two-dimensional array of cells 
(electrodes). A major advantage of digital microfluidic biochips is their 
reconfigurability, ease of integration and scalability [2]. 
 
Figure 1. A typical DMFB device [1] 
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The benefits of digital microfluidic biochips are as follows [3]: 
 Absence of mechanical components: All recycling operations are carried 
out between the upper and lower two layers of the bio-chip. 
 No need for channels: The gap between the two plates is filled by the filler 
fluid. 
 Ability to independently control droplets: to apply localized electric 
humidification force. 
 Controlling or preventing evaporation: The filler (oil) surrounding the 
droplets prevents evaporation. 
 Non-use of electric current: Despite capacitive currents, it does not occur 
to avoid direct sample heating and electrochemical reactions. 
 Compatibility with a wide variety of liquids: Most electrolyte solutions. 
 Near-full productivity of the sample or reactor: due to no loss of fluid to 
cover the ducts or fill the tanks. 
 Compatibility for Microscopic Applications: Glass substrate and Indium 
Tin Oxide (ITO) electrodes allow microscopic examination. 
 High Energy Efficiency: Each drop transfer consumes energy at the 
nanoscale or microwave scale. 
 High droplet speeds: up to 25 centimeters per second. 
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 Using Protocols Based on Equivalent Laboratory Liquid Chemistry: Users 
can scale, automate and embed proven experiments and protocols. 
 Maximum operational flexibility: Direct computer control at each step 
enables conditional execution of the next steps. 
As shown in Fig. (Fig: DMFB), the digital microfluidic biochip is composed of two 
plates coated with a hydrophobic layer of Teflon Amorphous Fluoroplastics. The 
bottom plate consists of an array of control electrodes, while the top plate consists 
of a single conductive electrode that covers the entire top plate [1]. The liquid 
droplets move between the top and bottom plates and into the fluid filling the 
space between the top and bottom plates. 
 
Figure 2. DMFB Structure 
All electrodes are capable of performing general microfluidic operations such as 
compound storage, splitting, etc., although some electrodes are equipped with 
special modules such as optical or heat sensors to detect and heat recrystallization 
if needed. As mentioned, all electrodes are capable of performing general 
microfluidic operations, so the electrodes can be used to perform general 
microfluidic operations if there is no need to use special modules embedded in 
digital microfluidic bio-chips (such as sensors, heaters, etc.). 
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Figure 3. Microfluidic operations from left to right; storage, transporting, merging, splitting and mixing [1] 
The first microfluidic operation is to keep the drop constant, by applying voltage 
to the electrode beneath the drop. This is important because all the droplets on the 
biochip must be kept in place during storage on the biochip, otherwise the droplet 
may slip and the process may be disrupted. 
The second microfluidic operation is droplet transfer which occurs by applying 
voltage to one of the adjacent electrodes and simultaneously deactivating the 
electrode below the droplet. 
The third microfluidic operation is to merge the two droplets together. In this 
operation, two droplets are moved adjacent to each other and then the electrode 
beneath one of the droplets is deactivated while the electrode is still active beneath 
the other droplet. 
The fourth microfluidic operation is to divide a drop into two droplets of 
approximately identical volumes; this involves activating electrodes adjacent to the 
droplet (left and right electrodes, or top and bottom electrodes) and simultaneously 
disabling the electrode beneath the droplet. Ideally, the large droplet will be split 
into two droplets with approximately equal volumes due to tendency to move 
towards the active electrodes. 
The fifth microfluidic operation is to combine two droplets to obtain a uniform 
and homogeneous combination of the two droplets; first, by using the merging 
operation, the two droplets are combined, then moved the droplet on a specified 
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path of electrodes for a specified period of time. The movement is to obtain a 
uniform and homogeneous droplet. 
Synthesis of digital microfluidic biochips consists of three primary stages: 
Scheduling, Placement, and Droplet Routing, and two preliminary stages of Pin-
Mapping and Pin Routing [11]. The following describes the structure of a digital 
microfluidic system and each step of the automation process for the physical design 
of a digital microfluidic biochip. 
 
Figure 4. Synthesis flow of DMFB devices [4] [5] [6] 
Scheduling is the first step in the synthesis of DMFBs. Each microfluidic operation 
is given an exact start and end time. The performance of the scheduling algorithm 
must be such as to ensure that no operations are initiated before the end of its 
parent operations and that there are sufficient resources available to execute the 
operations that are scheduled simultaneously [1]. 
After the scheduling phase is over, it is time to start the placement phase. The 
placement phase decides where to execute microfluidic operations on the surface 
of the DMFB device [1]. 
After the timing of the operations and the placement of the modules on the surface 
of the 2D array of electrodes, it is time for the droplet routing step. At this stage, 
the routing operation of the liquid droplets is performed to move between the 
input reservoirs and the modules, between the modules and the movement from 
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the modules to the output reservoirs. At the routing stage, it must be ensured that 
the droplet reaches its designated destination and does not interfere with other 
droplets [1]. 
After the droplet routing step is completed, an optional step is sometimes pin-
mapping. Digital microfluidic biochips pin-mapping schemes can be categorized 
as individually addressable pins (sometimes referred to as direct addressing), pin-
constrained and active-matrix. 
Finally, the last step in the synthesis is the routing of the wires. The electrodes are 
located on the bottom plate of the digital microfluidic bio-chip, and routing the 
wires is done beneath this substrate onto one or more layers of the printed circuit 
board (PCB) or other material including glass [7] or paper [8] [9]. 
Proposed solutions include pin-constrained DMFB architectures with the aim of 
outperforming previous architectures while improving the fault tolerance of the 
proposed architectures. 
Here are some overviews of suggested solutions: 
Time Overhead: We will have to use other modules due to permanent hardware 
faults in modules, which in most cases will result in increased operation time and 
droplet routing time. 
Space Overhead: Other modules should be used if possible, in order to avoid 
faulty modules. 
 
 
  7
The following can be mentioned in terms of improvements to the proposed 
DMFB architectures: 
 Improvements in DMFB hardware (reduction of DMFB dimensions, 
reduction of the number of electrodes and control pins used to drive the 
DMFB device) 
 Significantly decreasing the droplet routing time that the overall execution 
time of bioassays is decreased. 
 Adding hardware/software fault-tolerance capability so that even in the 
event of destructive (permanent) faults, the DMFB can continue to operate 
and perform biological tests. 
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C h a p t e r  2  
PROPOSED DMFB ARCHITECTURES 
In this section, we introduce and evaluate the performance of fault-tolerant digital 
microfluidic biochip architectures. In the process of designing the proposed 
architectures, special attention has been paid to improving fault tolerance. We will 
first introduce the benchmark architecture, which will be used to compare the 
performance of the proposed architectures in this chapter. 
Before presenting the proposed architectures, we introduce a set of commonly 
used bioassays along with their characteristics. We then introduce the proposed 
digital biochip architectures and examine the performance of the architectures 
assuming no faults and faults. Finally, we describe the addition and improvements 
on fault tolerance in digital pin-constrained biochips. Adding fault tolerance 
capability to this chapter is associated with the mixing modules along with the 
splitting/storing/detecting modules. 
 PCR or polymerase chain reaction is a method of amplifying small amounts 
of DNA or RNA for use in laboratory applications. Digital microfluidic 
biochips are used to perform a set of recursive PCR experiments. 
 
Figure 5. PCR Benchmark 
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 The in-vitro test refers to a series of diagnostic tests that use four human 
physiological substances or samples including plasma, serum, urine and 
saliva to determine the amount of glucose, lactate, pyruvate and glutamate 
to detect metabolic disorders [1]. In in-vitro testing, four physiological 
fluids are combined with four reactants, and the results are sent to a 
detection module embedded in the digital microfluidic biochip. 
 
Figure 6. In-Vitro Benchmark 
 Protein testing involves consecutive steps of mixing, splitting and 
detection. Depending on the number of bioassay nodes, we use seven 
different configurations of protein bioassays. 
 
Figure 7. Protein Benchmark 
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Following the introduction of the benchmark bioassays for digital microfluidic 
biochips, we present the specification of the benchmark tests based on the number 
of operation (including mixing, splitting, storage, detection, etc.) in the form of a 
table. 
Table 1. Benchmark Characteristics 
 
As shown in the table, the PCR test consists solely of mixing operations. The set 
of In-Vitro bioassays is composed of mixing and splitting operations; with the 
change in configuration from In-Vitro 1 to In-Vitro 5, the number of mixing and 
splitting operations increases proportionally. In relation to the set of protein 
bioassays, the mixing, splitting and storage operations are used; as shown in the 
storage column values, the protein set requires a large number of 
splitting/storage/detection modules to store the middle droplets. 
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BENCHMARK ARCHITECTURE 
The field-programmable pin-constrained (FPPC) architecture [10] is used as the 
benchmark architecture. The architecture is general-purpose and programmable, 
so it offers the capability to run a wide range of tests including PCR, In-Vitro and 
Protein. 
 
Figure 8. The FPPC Architecture 
  12
PROPOSED ARCHITECTURES 
The General-purpose Field-programmable Pin-Constrained (GFPC) 
Architecture 
The purpose of this architecture is to provide with minimum design size, number 
of electrodes and control pins, while also improving the performance level of 
digital microfluidic biochip. This has been accomplished by incorporating multiple 
paths for the routing of droplets on the surface of the digital microfluidic biochip 
[4]. 
 
Figure 9. The proposed GFPC Architecture 
Before considering the performance of general-purpose field-programmable pin-
constrained (GFPC) architecture, let's first consider the pin-mapping algorithm for 
the architecture. The pin-mapping pseudo-algorithm for the general-purpose field-
programmable pin-constrained architecture is illustrated below. 
The location of the vertical and horizontal routing columns should be determined 
according to the architectural dimensions; for this purpose, in lines 3 and 4, the 
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variables vrt and hrt are defined to store the location of the vertical and horizontal 
routing columns. 
 
After storing the location of the routing columns in the vrt and hrt variables, it is 
necessary to assign pins to each of the columns according to the type of column 
(vertical or horizontal). 
In lines 6 to 9, each of the values in the vrt variable is read and assigned shared pins 
1 to 3. In lines 10 through 12, each of the values stored in the hrt variable is read 
and assigned shared pins 4 to 6. Shared pins are used to reduce the total number 
of pins needed to address the electrodes of routing columns. 
After assigning pins to the electrodes of the routing columns, we proceed to assign 
pins to the mixing modules. In lines 14 to 18, the electrodes within the mixing 
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modules are assigned with the shared pins 7 to 12. Due to the need for separate 
controls for the I/O electrodes and the holder electrodes in the mixing modules, 
we assign separate pins to each I/O electrode and the holder. 
In the following, pin assignment to splitting/storage/detection modules is 
discussed. For this purpose, lines 20 to 23 allocate independent pins to 
input/output electrodes and holders of each splitting/storage/detection modules. 
Due to potential deadlocks in the routing process, a module is assigned as the 
routing buffer. In the last step of the pin mapping algorithm, lines 25 to 28 allocate 
independent pins to the I/O electrodes and holder for the routing buffer module. 
In the following, we examine the performance of general-purpose field-
programmable pin-constrained (GFPC) architecture in relation to the performance 
of the benchmark bioassays. 
The benchmark test column shows the name of the benchmark bioassay applied 
to the architecture. The chip dimensions column represents the dimensions of the 
of the biochip electrodes for executing microfluidic operations. 
The number of electrodes column represents the number of electrodes embedded 
in the surface of the digital microfluidic biochip. The pin number column indicates 
the number of control pins needed to control operations of the biochip. 
The microfluidic operation time column shows the time allotted to perform digital 
microfluidic operations (such as merging, mixing, splitting, storage, detection, etc.). 
The droplet routing column represents the droplet routing time on the surface of 
the electrodes during the bioassay execution. Droplet routing time includes droplet 
routing time from input dispensers to the modules, between the modules and from 
the modules to the output repositories. 
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Table 2. Comparing performance of the proposed GFPC architecture versus the FPPC benchmark 
architecture 
 
The total time column represents the total time the bioassay was performed on 
digital microfluidic biochip. The total time is obtained from the sum of the columns 
of the operation time and the droplet routing time. 
With regard to the dimensions of digital microfluidic biochip, the results show a 
33% improvement (which means that the dimensions are reduced). The results also 
show a 20% decrease in the number of electrodes. Results show a 3% decrease in 
the number of control pins. 
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Both architectures provide the same performance, while droplet routing is down 
17%. The table shows that the droplet routing times are much shorter compared 
to the time of the microfluidic operations, although due to the equality of the time 
of the microfluidic operations in both architectures, the reduction in droplet 
routing time is significant and reduces the total time required for bioassay execution 
by 2%. 
Field-programmable Pin-constrained Cell Array (FPCA) Architecture 
In the design of field-programmable pin-constrained Cell Array (FPCA) [5] 
architecture the cells are utilized as the basic structure; each cell comprises of a 
certain number of mixing modules as well as splitting/storage/detection modules. 
The overall structure of the FPCA architecture is a constructed of number of cells. 
For example, the FPCA architecture presented below is made up of four basic cells. 
Each cell has two mixing modules and four splitting/storage/detection modules. 
 
Figure 10. The proposed FPCA Architecture 
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Before examining the performance of FPCA architecture, we first examine the pin-
mapping algorithm for the architecture in question. The pin-mapping pseudo-
algorithm is shown below. 
 
The location of the vertical and horizontal routing columns should be determined 
according to the architectural dimensions; for this purpose, in lines 3 and 4, the 
variables vrt and hrt are defined to store the location of the vertical and horizontal 
routing columns. 
After storing the location of the routing columns in the vrt and hrt variables, it is 
necessary to assign pins to each of the columns according to the type of column 
(vertical or horizontal). 
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In lines 6 to 9, each of the values in the vrt variable is first read and then assigned 
to the shared pins 1 to 3. Shared pins are used to reduce the total number of pins 
needed to address the electrodes of routing columns. 
In lines 10 through 12, each of the values stored in the hrt variable is read and then 
assigned to the 4 to 6 shared pins. Shared pins are used to reduce the total number 
of pins needed to address the electrodes of routing columns. 
In the following, we investigate the performance of the FPCA architecture in 
relation to the performance of the benchmark FPPC architecture. 
The benchmark test column shows the name of the benchmark bioassay applied 
to the architecture. The chip dimensions column represents the dimensions of the 
of the biochip electrodes for executing microfluidic operations. 
The number of electrodes column represents the number of electrodes embedded 
in the surface of the digital microfluidic biochip. The pin number column indicates 
the number of control pins needed to control operations of the biochip. 
The microfluidic operation time column shows the time allotted to perform digital 
microfluidic operations (such as merging, mixing, splitting, storage, detection, etc.). 
The droplet routing column represents the droplet routing time on the surface of 
the electrodes during the bioassay execution. Droplet routing time includes droplet 
routing time from input reservoirs to the modules, between the modules and from 
the modules to the output reservoirs. 
The total time column represents the total time the bioassay was performed on 
digital microfluidic biochip. The total time is obtained from the sum of the columns 
of the operation time and the droplet routing time. 
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Here's a look at how different parameters of the FPCA architecture are compared 
to those of the FPPC architecture. 
Table 3. Comparing performance of the proposed FPCA architecture versus the FPPC benchmark 
architecture 
 
With regard to the dimensions of digital microfluidic biochip dimensions the 
results show a 10% improvement. It also shows a 1% decrease in the number of 
electrodes. Results show an 8% decrease in the number of control pins. 
Both architectures provide the same performance when it comes to microfluidic 
operations. There is a 12% reduction in droplet routing time. According to the 
table, it is observed that droplet routing times are much shorter compared to the 
time of microfluidic operations, although due to the equality of time of microfluidic 
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operations in both architectures, the reduction in droplet routing time in the FPCA 
architecture is considerable compared to the FPPC architecture and reduces the 
total bioassay time by 1%. 
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FAULT-TOLERANCE IN PROPOSED ARCHITECTURES 
In this section, we investigate the fault-tolerance in the presented GFPC and FPCA 
architectures and compare the fault-tolerance performance in the aforementioned 
architectures with respect to the fault-tolerance in the FPPC architecture. 
The fault-tolerance capability of in GFPC [4] and FPCA [5] architectures includes 
fault-tolerance in mixing modules, splitting/storage/detection modules, and 
droplet routing paths; as we will discuss each of these in detail later. 
Fault-Tolerance in Mixing Modules 
In this section, we describe the failure of mixing module and its impact on the 
bioassay process. 
 
Figure 11. Faults affecting mixing modules 
The use of mixing modules affected by permanent faults can disrupt the process 
of performing the bioassay. Simply put, if the electrode in the mixing module is 
defective when the droplet passes through the defective electrode, it will not be 
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possible to activate and apply the electric field to that electrode and thus the droplet 
will not be able to move. 
 
Figure 12. Placement of mixing microfluidic operation on faulty mixing modules 
 
Figure 13. Droplet routing of mixing microfluidic operation on faulty mixing modules 
Therefore, the processing of bioassay is interrupted. If the permanent fault in the 
mixing module electrode is not detected prior to performing the bioassay synthesis 
process, the faulty mixing module will be used in the bioassay execution process 
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and thus the execution process will be disrupted. The proposed solution is to 
modify the existing algorithms in order to skip the defective mixing module from 
the set of modules for bioassay execution. 
 
Figure 14. Placement of mixing microfluidic operation skipping faulty mixing modules 
 
Figure 15. Droplet routing of mixing microfluidic operation skipping faulty mixing modules 
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Fault-Tolerance in Splitting/Storage/Detection Modules 
In this section we describe the permanent faults in the division/storage/detection 
module and its impact on the bioassay execution process. If there are any 
permanent faults in the splitting/storage/detection module electrode prior to 
performing the bioassay synthesis process, it will result in disruption of the test 
execution process. 
 
Figure 16. Faults affecting splitting/storage/detection modules 
 
Figure 17. Placement of microfluidic operation on faulty splitting/storage/detection modules 
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Figure 18. Droplet routing of microfluidic operation on faulty splitting/storage/detection modules 
The proposed solution is to modify the existing algorithms in such a way as to skip 
the faulty splitting/storage/detection modules from the set of modules available 
for bioassay execution; therefore, no operations are inserted and thus there will be 
no droplets in the faulty splitting/storage/detection module. 
 
Figure 19. Placement of microfluidic operation skipping faulty splitting/storage/detection modules 
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Figure 20. Droplet routing of microfluidic operation skipping faulty splitting/storage/detection modules 
Fault-Tolerance of Droplet Routing Pathways 
Regarding the fault-tolerance of routing paths, since the proposed architectures 
provide multiple paths for droplet routing, alternative embedded paths can be used 
in the event of a permanent breakdown at one of the routing pathway electrodes. 
Whereas in the benchmark architecture there is only one path for droplet routing 
and any breakdown in the pathway electrodes will affect the performance of the 
DMFB architecture. 
Conclusion 
In this chapter, we first introduced a set of benchmark tests in relation to DMFB 
devices, and then presented the proposed fault-tolerant architectures. Then we 
compared the performance of the proposed architectures with the benchmark 
FPPC architecture. Finally, we explained the concepts of fault-tolerance in different 
parts of DMFB architectures and how to deal with the occurrence of permanent 
faults in each segment. 
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As detailed comparisons of the various parameters of the proposed architectures 
showed, the proposed architectures provide a better performance along with 
improved fault-tolerance. 
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C h a p t e r  3  
FAULT-TOLERANCE EVALUATION RESULTS 
After introducing the proposed architectures in the previous chapter, this chapter 
examines the performance of the proposed architectures in the event of a 
breakdown in different parts of the DMFB architecture. We first compare the 
performance of the proposed architectures in the presence of the failure of the 
mixing module. Next, we examine the performance of the proposed architectures 
compared to the benchmark architecture in the presence of 
splitting/storage/detection module failures. Finally, we refer to fault-tolerance in 
routing buses [6]. 
As can be seen in the following table, in the case of the GFPC and FPCA 
architectures, the dimensions of the array are 21 × 11 and 21 × 17, with 
respectively, 169 and 235 electrodes and 237 and 58 control pins. 
As shown in table, in case of GFPC architecture, there is a 42% reduction in array 
dimensions, 29% decrease in the number of electrodes, and an 8% decrease in the 
number of pins compared to the FPPC architecture. In case of FPCA architecture 
there is a 10% reduction in array size, 1% decrease in the number of electrodes and 
an 8% decrease in the number of control pins. 
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Table 4. Characteristics of DMFB architectures; GFPC versus FPPC versus FPCA 
 
In simulating the occurrence of permanent faults in the proposed architectures, 
only the first (most used) module of any type (mixing module, or 
splitting/storage/detection module) is assumed to be faulty. 
Failure in Mixing Modules 
In DMFB architectures, a group of shared pins are assigned to the modules; 
therefore, even if one of the mixing modules fails, it may be time-consuming or 
even impossible to use. Therefore, we modify the existing algorithms so that the 
synthesis flow skips the faulty module, and instead uses other existing modules if 
possible. 
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Comparison of Mixing Module Failures in GFPC Architecture versus the 
FPPC Benchmark Architecture 
Previously, we compared the performance of the proposed GFPC architecture and 
the FPPC benchmark architecture in the normal conditions without the occurrence 
of permanent faults. In this section, we intend to examine the performance of the 
aforementioned architectures in the presence of permanent faults in the mixing 
module [6]. It should be noted that in connection with the assumption of 
permanent malfunction of the mixing module, we used the first module (the most 
frequently used module) as the faulty module. 
The benchmark column represents the type of bioassay applied on the DMFB. The 
operation time column represents the time allocated to performing digital 
microfluidic operations, including mixing, splitting, storage, detection, etc. Each of 
the healthy and faulty sub-columns are further divided into FP and GF. Healthy 
represents the normal operation time and no faults. In contrast, the Faulty sub-
column represents the operation time in the event of a permanent fault in the 
mixing module in the GFPC and FPPC architectures. 
The routing time column represents the time allotted for routing the droplets from 
the input reservoirs to the modules, between the modules and from the modules 
to the output reservoirs. The routing column is divided into two healthy and faulty 
sub-columns; each of the healthy and faulty sub-columns is in turn divided into 
two FP and GF. The healthy sub-column represents the droplet routing time in 
the normal state without any faults. Faulty sub-column indicates the droplet routing 
time in the event of a permanent fault in the mixing module in the GFPC (GF) 
and benchmark FPPC (FP) architectures. 
The total time column represents the total time of the test and, in other words, the 
sum of the columns of the operation time and droplet routing time.  
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As shown in the table the two bottom rows indicate the average improvement and 
the average overhead. The average overhead row represents the overhead rate 
compared to the performance of each of the architectures in both normal and 
faulty performance modes. 
Table 5. Comparing performance of GFPC versus FPPC architectures in presence of faulty mixing 
module 
 
 
  32
Comparison of Mixing Module Failures in FPCA Architecture versus the 
FPPC Benchmark Architecture 
In this section, we intend to examine the performance of the FPCA and benchmark 
FPPC architectures in the presence of permanent faults in the mixing module [6]. 
It should be noted that in connection with the assumption of permanent 
malfunction of the mixing module, we used the first module (the most frequently 
used module) as the faulty module. 
The benchmark column represents the type of bioassay applied on the DMFB. The 
operation time column represents the time allocated to performing digital 
microfluidic operations, including mixing, splitting, storage, detection, etc. Each of 
the healthy and defective sub-columns are further divided into FP and CA. Healthy 
represents the normal operation time and no faults. In contrast, the Faulty sub-
column represents the operation time in the event of a permanent fault in the 
mixing module in the FPCA and FPPC architectures. 
The routing time column represents the time allotted for routing the droplets from 
the input reservoirs to the modules, between the modules and from the modules 
to the output reservoirs. The routing column is divided into two healthy and faulty 
sub-columns; each of the healthy and faulty sub-columns is in turn divided into 
two FP and CA. The healthy sub-column represents the droplet routing time in the 
normal state without any faults. Faulty sub-column indicates the droplet routing 
time in the event of a permanent fault in the mixing module in the FPCA (CA) and 
benchmark FPPC (FP) architectures. 
The total time column represents the total time of the test and, in other words, the 
sum of the columns of the operation time and droplet routing time. 
As shown in the table the two bottom rows indicate the average improvement and 
the average overhead. The average overhead row represents the overhead rate 
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compared to the performance of each of the architectures in both normal and 
faulty performance modes. 
Table 6. Comparing performance of FPCA versus FPPC architectures in presence of faulty mixing module 
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Failure in Splitting/Storage/Detection Modules 
In this section, we discuss the splitting/storage/detection module failure and its 
impact on the performance of proposed architectures. In the case of 
splitting/storing/detection modules if the input electrode or the holding electrode 
fails, the only way is not to use the module [6]. Next, we investigate the effect of 
splitting/storage/detection module failure on the performance of architectures. 
Comparison of Splitting/Storage/Detection Module Failures in GFPC 
Architecture versus the FPPC Benchmark Architecture 
In this section, we intend to examine the performance of the aforementioned 
architectures in the presence of permanent faults in the splitting/storage/detection 
module. It should be noted that in connection with the assumption of permanent 
malfunction of the splitting/storage/detection module, we used the first module 
(the most frequently used module) as the faulty module. 
The benchmark column represents the type of bioassay applied on the DMFB. The 
operation time column represents the time allocated to performing digital 
microfluidic operations, including mixing, splitting, storage, detection, etc. Each of 
the healthy and faulty sub-columns are further divided into FP and GF. Healthy 
represents the normal operation time and no faults. In contrast, the Faulty sub-
column represents the operation time in the event of a permanent fault in the 
splitting/storage/detection module in the GFPC and FPPC architectures. 
The routing time column represents the time allotted for routing the droplets from 
the input reservoirs to the modules, between the modules and from the modules 
to the output reservoirs. The routing column is divided into two healthy and faulty 
sub-columns; each of the healthy and faulty sub-columns is in turn divided into 
two FP and GF. The healthy sub-column represents the droplet routing time in 
the normal state without any faults. Faulty sub-column indicates the droplet routing 
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time in the event of a permanent fault in the splitting/storage/detection module in 
the GFPC (GF) and benchmark FPPC (FP) architectures. 
Table 7. Comparing performance of GFPC versus FPPC architectures in presence of faulty 
splitting/storage/detection module 
 
The total time column represents the total time of the test and, in other words, the 
sum of the columns of the operation time and droplet routing time. 
As shown in the table the two bottom rows indicate the average improvement and 
the average overhead. The average overhead row represents the overhead rate 
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compared to the performance of each of the architectures in both normal and 
faulty performance modes. 
Comparison of Splitting/Storage/Detection Module Failures in FPCA 
Architecture versus the FPPC Benchmark Architecture 
In this section, we intend to examine the performance of the aforementioned 
architectures in the presence of permanent faults in the splitting/storage/detection 
module [6]. It should be noted that in connection with the assumption of 
permanent malfunction of the splitting/storage/detection module, we used the 
first module (the most frequently used module) as the faulty module. 
The benchmark column represents the type of bioassay applied on the DMFB. The 
operation time column represents the time allocated to performing digital 
microfluidic operations, including mixing, splitting, storage, detection, etc. Each of 
the healthy and faulty sub-columns are further divided into FP and CA. Healthy 
represents the normal operation time and no faults. In contrast, the Faulty sub-
column represents the operation time in the event of a permanent fault in the 
splitting/storage/detection module in the FPCA and FPPC architectures. 
The routing time column represents the time allotted for routing the droplets from 
the input reservoirs to the modules, between the modules and from the modules 
to the output reservoirs. The routing column is divided into two healthy and faulty 
sub-columns; each of the healthy and faulty sub-columns is in turn divided into 
two FP and CA. The healthy sub-column represents the droplet routing time in the 
normal state without any faults. Faulty sub-column indicates the droplet routing 
time in the event of a permanent fault in the splitting/storage/detection module in 
the FPCA (CA) and benchmark FPPC (FP) architectures. 
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Table 8. Comparing performance of FPCA versus FPPC architectures in presence of faulty 
splitting/storage/detection module 
 
Conclusion 
In this chapter, we presented the simulation results of faults affecting modules of 
various DMFB architectures; we did the simulations for mixing modules and the 
splitting/storage/detection modules. 
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